二甲双胍预防严重慢性肾脏病及其相关矿物质骨代谢紊乱
该研究在腺嘌呤诱导的CKD-MBD大鼠模型中观察到,二甲双胍(200 mg/kg/天)可阻止向严重CKD进展,避免高磷血症和低钙血症,并预防血管钙化及高骨转换病。在华法林诱导的血管钙化模型中,二甲双胍未减少钙化,提示其获益主要来自改善肾功能。
要点
- 二甲双胍可阻止腺嘌呤大鼠向严重CKD进展并保护钙磷稳态。
- 二甲双胍预防CKD相关血管钙化和高骨转换病,肾脏炎症纤维化减轻。
- 对华法林诱导的血管钙化无直接抑制作用,获益可能依赖肾功能改善。
核心结论
- 二甲双胍可预防严重CKD的发展并维持钙磷稳态,进而预防血管钙化和高骨转换病。
研究设计与样本
- 研究采用腺嘌呤饮食诱导的CKD-MBD大鼠模型,二甲双胍200 mg/kg/天或溶媒从诱导后一周开始给药。
- 另采用华法林诱导的血管钙化大鼠模型,二甲双胍200 mg/kg/天或溶媒给药十周以评估直接效应。
主要发现
- 腺嘌呤大鼠出现严重稳定CKD、明显高磷血症和低钙血症,并发生动脉钙化和高骨转换病。
- 二甲双胍组未发生高磷血症或低钙血症,未发生血管钙化,并抑制向高骨转换病进展。
- 二甲双胍组肾脏细胞浸润、纤维化和炎症显著减轻。
- 在华法林诱导的血管钙化模型中,二甲双胍未减少主动脉或小血管钙化。
临床怎么用
- 提示二甲双胍可能对CKD进展及CKD-MBD具有保护作用,但需临床研究验证。
- 其血管钙化保护作用可能继发于肾功能改善,而非直接抑制钙化。
局限性
- 证据来自动物模型,不能直接外推至人类。
- 原文未报告样本量、P值及置信区间等统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) causes dysregulation of mineral metabolism, vascular calcification and renal osteodystrophy, an entity called 'CKD-Mineral and Bone Disorder' (CKD-MBD). Here we determine whether metformin, an anti-diabetic drug, exerts favorable effects on progressive, severe CKD and concomitant mineral metabolism disturbances. Rats with CKD-MBD, induced by a 0.25% adenine diet for eight weeks, were treated with 200 mg/kg/day metformin or vehicle from one week after CKD induction onward. Severe, stable CKD along with marked hyperphosphatemia and hypocalcemia developed in these rats which led to arterial calcification and high bone turnover disease. Metformin protected from development toward severe CKD. Metformin-treated rats did not develop hyperphosphatemia or hypocalcemia and this prevented the development of vascular calcification and inhibited the progression toward high bone turnover disease. Kidneys of the metformin group showed significantly less cellular infiltration, fibrosis and inflammation. To study a possible direct effect of metformin on the development of vascular calcification, independent of its effect on renal function, metformin (200 mg/kg/day) or vehicle was dosed for ten weeks to rats with warfarin-induced vascular calcification. The drug did not reduce aorta or small vessel calcification in this animal model. Thus, metformin protected against the development of severe CKD and preserved calcium phosphorus homeostasis. As a result of its beneficial impact on renal function, associated comorbidities such as vascular calcification and high bone turnover disease were also prevented.
引用
- Neven E, Vervaet B, Brand K, et al. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int. 2018. PMID: 29716795. doi:10.1016/j.kint.2018.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。